Abstract
Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating biaryl P4 groups, producing highly potent inhibitors with encouraging oral pharmacokinetic profiles and significant but sub-optimal anticoagulant activities.
MeSH terms
-
Animals
-
Anticoagulants / chemistry
-
Anticoagulants / pharmacokinetics
-
Anticoagulants / pharmacology
-
Drug Design
-
Factor Xa Inhibitors*
-
Male
-
Models, Molecular
-
Pyrrolidinones / chemistry*
-
Pyrrolidinones / pharmacokinetics
-
Pyrrolidinones / pharmacology*
-
Rats
-
Rats, Sprague-Dawley
-
Serine Proteinase Inhibitors / chemistry*
-
Serine Proteinase Inhibitors / pharmacokinetics
-
Serine Proteinase Inhibitors / pharmacology*
-
Structure-Activity Relationship
-
Sulfonamides / chemistry
-
Sulfonamides / pharmacokinetics
-
Sulfonamides / pharmacology
Substances
-
Anticoagulants
-
Factor Xa Inhibitors
-
Pyrrolidinones
-
Serine Proteinase Inhibitors
-
Sulfonamides